Combination therapy for treatment of FIV infection

Abstract

The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor.

1 . A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT) and another nucleoside analog.  
     
     
         2 . The method according to  claim 1 , wherein said another nucleoside analog is 3TC.  
     
     
         3 . The method according to  claim 1 , wherein said feline animal receives bone marrow transplantation after total body irradiation.  
     
     
         4 . The method according to  claim 3 , wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.  
     
     
         5 . A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT), another nucleoside analog and an inhibitor of a retroviral protease.  
     
     
         6 . The method according to  claim 5 , wherein said another nucleoside analog is 3TC.  
     
     
         7 . The method according to  claim 5 , wherein said inhibitor of a retroviral protease is selected from the group consisting of HIV protease inhibitors and FIV protease inhibitors.  
     
     
         8 . The method accoding to  claim 5 , wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in  FIG. 4 .  
     
     
         9 . The method according to  claim 5 , wherein said another nucleoside analog is 3TC and said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in  FIG. 4 .  
     
     
         10 . The method according to  claim 5 , wherein said feline animal receives bone marrow transplantation after total body irradiation.  
     
     
         11 . The method according to  claim 10 , wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.  
     
     
         12 . A kit comprising in one or more containers AZT, another nucleoside analog and an inhibitor of a retroviral protease.  
     
     
         13 . The kit according to  claim 12 , wherein said another nucleoside analog is 3TC.  
     
     
         14 . The kit according to  claim 12 , wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in  FIG. 4 .  
     
     
         15 . The kit according to  claim 12 , wherein said another nucleoside analog is 3TC and said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in  FIG. 4 .